A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence
Launched by ABBVIE · Nov 15, 2021
Trial Information
Current as of May 24, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • - Completion of all phases of the lead-in Phase 3 study (Screening Period, Treatment Period \[randomization/treatment with 4-month follow-up visit\] and Study Exit visit)
- Exclusion Criteria:
- • Any medical condition that may put the participant at increased medical risk with exposure to BOTOX, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other condition that might interfere with neuromuscular function
- • Participant has an anticipated need for treatment with botulinum toxin of any serotype for any indication during the study (other than study intervention)
- • Anticipated need for surgery or overnight hospitalization during the study
- • Females who are pregnant or breastfeeding and are considering becoming pregnant or donating eggs during the study
- • Known immunization or hypersensitivity to any botulinum toxin serotype
- • History of clinically significant (per investigator's judgment) drug or alcohol abuse within the last 6 months
- • Tattoos, jewelry, or clothing that cannot be removed, and that obscure the target area of interest
About Abbvie
AbbVie is a global biopharmaceutical company dedicated to developing innovative therapies that address complex health challenges. Founded in 2013 as a spin-off from Abbott Laboratories, AbbVie focuses on key therapeutic areas, including immunology, oncology, neuroscience, and virology. The company is committed to advancing scientific research and delivering groundbreaking treatments that enhance patient outcomes and quality of life. With a robust pipeline and a strong emphasis on collaboration, AbbVie strives to transform the future of medicine through its commitment to clinical excellence and patient-centered approaches.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Glendale, Arizona, United States
Scottsdale, Arizona, United States
Encino, California, United States
Newport Beach, California, United States
San Diego, California, United States
Santa Monica, California, United States
Solana Beach, California, United States
Westport, Connecticut, United States
Bradenton, Florida, United States
West Palm Beach, Florida, United States
Indianapolis, Indiana, United States
Metairie, Louisiana, United States
New Orleans, Louisiana, United States
Baltimore, Maryland, United States
Hunt Valley, Maryland, United States
Montclair, New Jersey, United States
New York, New York, United States
Chapel Hill, North Carolina, United States
Wilmington, North Carolina, United States
Dublin, Ohio, United States
Newtown Square, Pennsylvania, United States
Nashville, Tennessee, United States
Dallas, Texas, United States
Arlington, Virginia, United States
Spokane, Washington, United States
Vancouver, British Columbia, Canada
Burlington, Ontario, Canada
Cobourg, Ontario, Canada
Richmond Hill, Ontario, Canada
Patients applied
Trial Officials
ALLERGAN INC.
Study Director
Allergan
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials